{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:17:52Z","timestamp":1790306272205,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["ASH Graduate Hematology Award"],"award-info":[{"award-number":["ASH Graduate Hematology Award"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    KMT2A-rearranged acute myeloid leukemia is driven by epigenetic dependencies yet remains clinically resistant to therapies targeting individual regulators, indicating that resistance reflects compensatory regulation across an epigenetic network. A systematic understanding of this compensatory network has been lacking. To address this gap, we utilized Perturb-seq screening to systematically map the functional architecture of this network. We uncovered a compensatory epigenetic circuit, where a synergistic hub including KAT6A, Menin, and DOT1L converges to silence a core differentiation program (the \u2018Myeloid Program\u2019), thereby maintaining leukemic identity. The activity of this program strongly correlated with favorable survival in large patient cohorts. While individual perturbations of hub components only partially derepress this program, their simultaneous pharmacological inhibition collapses the circuit\u2019s buffering capacity, leading to robust reactivation of the Myeloid Program and potent synergistic anti-leukemic activity. Our model also shows that disruption of antagonistic regulators of the Myeloid Program, such as the PRC1.1 component\n                    <jats:italic>PCGF1<\/jats:italic>\n                    , confers strong resistance to DOT1L inhibition. Finally, the Myeloid Program is a predictive biomarker, where high baseline activity defined a vulnerable state that could be selectively targeted by MEK, AKT, and mTOR inhibitors. Together, these findings establish a framework for identifying circuit-level epigenetic compensation and for rationally designing precision combination therapies that restore differentiation or target state-dependent vulnerabilities in acute myeloid leukemia.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-02917-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:52:47Z","timestamp":1774425167000},"page":"996-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia"],"prefix":"10.1038","volume":"40","author":[{"given":"Sajesan","family":"Aryal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-8323","authenticated-orcid":false,"given":"Brittany M.","family":"Curtiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3242-1518","authenticated-orcid":false,"given":"Xinyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2458-2522","authenticated-orcid":false,"given":"Changde","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2917_CR1","doi-asserted-by":"crossref","unstructured":"Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5:33.","DOI":"10.3390\/jcm5030033"},{"key":"2917_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, Soleimani Samarkhazan H, Asadi M, Zabihi M, Parkhideh S, Mohammadi MH. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13:73.","journal-title":"Biomark Res"},{"key":"2917_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201384.","journal-title":"J Clin Oncol"},{"key":"2917_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024;25:1310\u201324.","journal-title":"Lancet Oncol"},{"key":"2917_CR5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/2159-8290.CD-20-1459","volume":"12","author":"F Yan","year":"2022","unstructured":"Yan F, Li J, Milosevic J, Petroni R, Liu S, Shi Z, et al. KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene-expression programs. Cancer Discov. 2022;12:792\u2013811.","journal-title":"Cancer Discov"},{"key":"2917_CR6","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1182\/bloodadvances.2020003490","volume":"6","author":"T Katsumoto","year":"2022","unstructured":"Katsumoto T, Ogawara Y, Yamagata K, Aikawa Y, Goitsuka R, Nakamura T, et al. MOZ is critical for the development of MOZ\/MLL fusion-induced leukemia through regulation of Hoxa9\/Meis1 expression. Blood Adv. 2022;6:5527\u201337.","journal-title":"Blood Adv"},{"key":"2917_CR7","doi-asserted-by":"crossref","unstructured":"Schurer A, Glushakow-Smith SG, Gritsman K. Targeting chromatin modifying complexes in acute myeloid leukemia. Stem Cells Transl Med. 2025;14:szae089.","DOI":"10.1093\/stcltm\/szae089"},{"key":"2917_CR8","first-page":"258","volume":"25","author":"CE Sparbier","year":"2023","unstructured":"Sparbier CE, Gillespie A, Gomez J, Kumari N, Motazedian A, Chan KL, et al. Targeting Menin disrupts the KMT2A\/B and polycomb balance to paradoxically activate bivalent genes. Nat Cell Biol. 2023;25:258\u201372.","journal-title":"Nat Cell Biol"},{"key":"2917_CR9","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood.2023023644","volume":"144","author":"X Zhou","year":"2024","unstructured":"Zhou X, Zhang L, Aryal S, Veasey V, Tajik A, Restelli C, et al. Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia. Blood. 2024;144:2018\u201332.","journal-title":"Blood"},{"key":"2917_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-024-01610-0","volume":"17","author":"M Sheridan","year":"2024","unstructured":"Sheridan M, Maqbool MA, Largeot A, Clayfield L, Xu J, Moncaut N, et al. The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency. J Hematol Oncol. 2024;17:91.","journal-title":"J Hematol Oncol"},{"key":"2917_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.cell.2016.11.038","volume":"167","author":"A Dixit","year":"2016","unstructured":"Dixit A, Parnas O, Li B, Chen J, Fulco CP, Jerby-Arnon L, et al. Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell. 2016;167:1853\u201366.e17.","journal-title":"Cell"},{"key":"2917_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fcell.2019.00081","volume":"7","author":"AKN Chan","year":"2019","unstructured":"Chan AKN, Chen CW. Rewiring the epigenetic networks in MLL-rearranged leukemias: epigenetic dysregulation and pharmacological interventions. Front Cell Dev Biol. 2019;7:81.","journal-title":"Front Cell Dev Biol"},{"key":"2917_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fonc.2017.00241","volume":"7","author":"R Lu","year":"2017","unstructured":"Lu R, Wang GG. Pharmacologic targeting of chromatin modulators as therapeutics of acute myeloid leukemia. Front Oncol. 2017;7:241.","journal-title":"Front Oncol"},{"key":"2917_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2015.140822","volume":"101","author":"F Pastore","year":"2016","unstructured":"Pastore F, Levine RL. Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Haematologica. 2016;101:269\u201378.","journal-title":"Haematologica"},{"key":"2917_CR15","doi-asserted-by":"publisher","first-page":"e1007105","DOI":"10.1371\/journal.pgen.1007105","volume":"13","author":"JL Anderson","year":"2017","unstructured":"Anderson JL, Mulligan TS, Shen MC, Wang H, Scahill CM, Tan FJ, et al. mRNA processing in mutant zebrafish lines generated by chemical and CRISPR-mediated mutagenesis produces unexpected transcripts that escape nonsense-mediated decay. PLoS Genet. 2017;13:e1007105.","journal-title":"PLoS Genet"},{"key":"2917_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12028-5","volume":"10","author":"R Tuladhar","year":"2019","unstructured":"Tuladhar R, Yeu Y, Tyler Piazza J, Tan Z, Rene Clemenceau J, Wu X, et al. CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation. Nat Commun. 2019;10:4056.","journal-title":"Nat Commun"},{"key":"2917_CR17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cell.2016.05.053","volume":"165","author":"MW Popp","year":"2016","unstructured":"Popp MW, Maquat LE. Leveraging rules of nonsense-mediated mRNA decay for genome engineering and personalized medicine. Cell. 2016;165:1319\u201322.","journal-title":"Cell"},{"key":"2917_CR18","doi-asserted-by":"crossref","unstructured":"Zeng AGX, Iacobucci I, Shah S, Mitchell A, Wong G, Bansal S, et al. Single-cell transcriptional atlas of human hematopoiesis reveals genetic and hierarchy-based determinants of aberrant AML differentiation. Blood Cancer Discov. 2025:6:307\u201324.","DOI":"10.1158\/2643-3230.BCD-24-0342"},{"key":"2917_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.stem.2008.11.015","volume":"4","author":"TC Somervaille","year":"2009","unstructured":"Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM, et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell. 2009;4:129\u201340.","journal-title":"Cell Stem Cell"},{"key":"2917_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, et al. A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36:660\u201373 e11.","journal-title":"Cancer Cell"},{"key":"2917_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","volume":"560","author":"JB Baell","year":"2018","unstructured":"Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, et al. Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth. Nature. 2018;560:253\u20137.","journal-title":"Nature"},{"key":"2917_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2304","volume":"3","author":"W Yu","year":"2012","unstructured":"Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012;3:1288.","journal-title":"Nat Commun"},{"key":"2917_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nchembio.1331","volume":"9","author":"W Kim","year":"2013","unstructured":"Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013;9:643\u201350.","journal-title":"Nat Chem Biol"},{"key":"2917_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3324\/haematol.2012.074195","volume":"98","author":"AT Thiel","year":"2013","unstructured":"Thiel AT, Feng Z, Pant DK, Chodosh LA, Hua X. The trithorax protein partner menin acts in tandem with EZH2 to suppress C\/EBPalpha and differentiation in MLL-AF9 leukemia. Haematologica. 2013;98:918\u201327.","journal-title":"Haematologica"},{"key":"2917_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","volume":"125","author":"B Xu","year":"2015","unstructured":"Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2015;125:346\u201357.","journal-title":"Blood"},{"key":"2917_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524\u20138.","journal-title":"Nature"},{"key":"2917_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","volume":"20","author":"KM Bernt","year":"2011","unstructured":"Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20:66\u201378.","journal-title":"Cancer Cell"},{"key":"2917_CR28","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/leu.2016.327","volume":"31","author":"C Dafflon","year":"2017","unstructured":"Dafflon C, Craig VJ, Mereau H, Grasel J, Schacher Engstler B, Hoffman G, et al. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia. 2017;31:1269\u201377.","journal-title":"Leukemia"},{"key":"2917_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00826-6","volume":"13","author":"W Fiskus","year":"2023","unstructured":"Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023;13:53.","journal-title":"Blood Cancer J"},{"key":"2917_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2022.2163242","volume":"38","author":"A Negri","year":"2023","unstructured":"Negri A, Marozzi M, Trisciuoglio D, Rotili D, Mai A, Rizzi F. Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells. J Enzym Inhib Med Chem. 2023;38:2163242.","journal-title":"J Enzym Inhib Med Chem"},{"key":"2917_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13578-017-0184-0","volume":"7","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Dong W, Zhu J, Wang L, Wu X, Shan H. Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. Cell Biosci. 2017;7:56.","journal-title":"Cell Biosci"},{"key":"2917_CR32","doi-asserted-by":"crossref","unstructured":"Gordon SJV, Perner F, MacPherson L, Fennell KA, Wenge DV, Bourgeois W, et al. Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia. Cancer Discov. 2025;15:2117\u201338.","DOI":"10.1158\/2159-8290.CD-24-1517"},{"key":"2917_CR33","doi-asserted-by":"crossref","unstructured":"Olsen SN, Anderson B, Hatton C, Chu Z, Simpkins C, Wen Y, et al. Combined inhibition of KAT6A\/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. Cell Rep Med. 2025;6:102192.","DOI":"10.1016\/j.xcrm.2025.102192"},{"key":"2917_CR34","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130:981\u201397.","journal-title":"J Clin Invest"},{"key":"2917_CR35","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","volume":"6","author":"MW Kuhn","year":"2016","unstructured":"Kuhn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016;6:1166\u201381.","journal-title":"Cancer Discov"},{"key":"2917_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1182\/blood-2023-185561","volume":"142","author":"N Scheidegger","year":"2023","unstructured":"Scheidegger N, Alexe G, Khalid D, Ries RE, Wang J, Alonzo TA, et al. Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A-Rearranged RAS Pathway-Mutant Acute Leukemia. Blood. 2023;142:166.","journal-title":"Blood"},{"key":"2917_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0092-8674(95)90401-8","volume":"80","author":"CJ Marshall","year":"1995","unstructured":"Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179\u201385.","journal-title":"Cell"},{"key":"2917_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc989","volume":"3","author":"DG Tenen","year":"2003","unstructured":"Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003;3:89\u2013101.","journal-title":"Nat Rev Cancer"},{"key":"2917_CR39","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41587-020-0470-y","volume":"38","author":"JM Replogle","year":"2020","unstructured":"Replogle JM, Norman TM, Xu A, Hussmann JA, Chen J, Cogan JZ, et al. Combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted sequencing. Nat Biotechnol. 2020;38:954\u201361.","journal-title":"Nat Biotechnol"},{"key":"2917_CR40","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1182\/bloodadvances.2021004469","volume":"5","author":"L Zhao","year":"2021","unstructured":"Zhao L, Zhang P, Galbo PM, Zhou X, Aryal S, Qiu S, et al. Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia. Blood Adv. 2021;5:4727\u201340.","journal-title":"Blood Adv"},{"key":"2917_CR41","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067\u201373.","journal-title":"Nature"},{"key":"2917_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn5400","volume":"17","author":"X Zhou","year":"2025","unstructured":"Zhou X, Moreira S, Restelli C, Wang H, Jahangiri S, Aryal S, et al. Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models. Sci Transl Med. 2025;17:eadn5400.","journal-title":"Sci Transl Med"},{"key":"2917_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06995-x","volume":"15","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zhou X, Aryal S, Veasey V, Zhang P, Li FJ, et al. CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator. Cell Death Dis. 2024;15:627.","journal-title":"Cell Death Dis"},{"key":"2917_CR44","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.122.059713","volume":"146","author":"Y Tang","year":"2022","unstructured":"Tang Y, Aryal S, Geng X, Zhou X, Fast VG, Zhang J, et al. TBX20 improves contractility and mitochondrial function during direct human cardiac reprogramming. Circulation. 2022;146:1518\u201336.","journal-title":"Circulation"},{"key":"2917_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41375-022-01741-8","volume":"37","author":"X Zhou","year":"2023","unstructured":"Zhou X, Zhang P, Aryal S, Zhang L, Lu R. UTX loss alters therapeutic responses in KMT2A-rearranged acute myeloid leukemia. Leukemia. 2023;37:226\u201330.","journal-title":"Leukemia"},{"key":"2917_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","volume":"5","author":"R Ihaka","year":"1996","unstructured":"Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:299\u2013314.","journal-title":"J Comput Graph Stat"},{"key":"2917_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"2917_CR48","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","volume":"67","author":"H Zou","year":"2005","unstructured":"Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc B. 2005;67:301\u201320.","journal-title":"J R Stat Soc B"},{"key":"2917_CR49","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.molcel.2023.03.013","volume":"83","author":"JE Otto","year":"2023","unstructured":"Otto JE, Ursu O, Wu AP, Winter EB, Cuoco MS, Ma S, et al. Structural and functional properties of mSWI\/SNF chromatin remodeling complexes revealed through single-cell perturbation screens. Mol Cell. 2023;83:1350\u201367 e7.","journal-title":"Mol Cell"},{"key":"2917_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09186-x","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng F, Kovacs IA, Barabasi AL. Network-based prediction of drug combinations. Nat Commun. 2019;10:1197.","journal-title":"Nat Commun"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02917-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02917-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02917-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:13:24Z","timestamp":1778109204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02917-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2917"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02917-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}